Cilo Cybin to Debut on JSE AltX Market with $3M ALPS Investment

  • Cilo Cybin Holdings to list on JSE AltX market with $3M investment from ALPS.
  • Strategic move to target biotech, biohacking, and pharmaceutical sectors for personalized health solutions.
  • Board of directors includes professionals from South Africa and Malaysia for diverse expertise.

Satrix JSE

Cilo Cybin Holdings Limited, incorporated in South Africa, is set to list on the JSE’s AltX market. The company, registered on February 23, 2022, will begin trading on June 25, 2024. Cilo Cybin will list all 71,017,906 ordinary shares as a Special Purpose Acquisition Company (SPAC). The JSE share code is “CCC” with ISIN: ZAE000310397.

Company Background

Cilo Cybin was founded by Gabriel Theron. The company aims to invest in the biotech, biohacking, and pharmaceutical sectors. They focus on using Artificial Intelligence (AI) and medical expertise to deliver personalized health solutions. Their goal is to improve customer health, performance, and longevity.

Listing Requirements

Cilo Cybin meets the JSE AltX minimum issued capital requirement of R50 million. The company also meets the 10% public shareholder spread requirement. These criteria are essential for their listing as a SPAC.

Investment Strategy

Cilo Cybin plans to acquire and invest in businesses within the biotech, biohacking, and pharmaceutical industries. The company seeks assets that can enhance their service and product offerings. They aim to improve profitability and maximize shareholder returns.

Key Investment Criteria

  • Assets in the pharmaceutical, biotech, or biohacking sectors
  • Globally positioned assets
  • Potential for cash generation or value increase

ALPS and Dr. Tham Investment

ALPS and Dr. Tham each subscribed for 28,762,252 ordinary shares in Cilo Cybin. This investment represents a 40.5% shareholding for each, totaling USD 3 million. ALPS, based in Kuala Lumpur, Malaysia, is a biotech research, medical, and wellness company. They focus on predictive, precision, and preventive health management.

Synergies with ALPS

ALPS and Cilo Cybin share a mutual focus on personalized and preventative medicine. Both companies work in the medicinal cannabis and psychedelic products sectors. ALPS’ merger with Globalink Investment Inc., valued at USD 1.6 billion, will form Alps Life Science Inc., expected to list on Nasdaq.

Company Management

Cilo Cybin’s board of directors includes a mix of South African and Malaysian nationals. The CEO is Gabriel Theron, and the CFO is HB Aucamp. Dr. Seng Kong Tham serves as the non-executive chairman.

Board of Directors

Gabriel Theron43South AfricanChief Executive Officer, Founder
HB Aucamp74South AfricanChief Financial Officer
Dr. Seng Kong Tham55MalaysianNon-executive Chairman
Sakekile Baduza45South AfricanLead Independent Non-Executive Director
Jessica Moodley Theron42South AfricanNon-executive Director
Yoke Ling Chew53MalaysianNon-executive Director
Mohd Razef Bin Abdullah74MalaysianIndependent Non-Executive Director
Lisa Teoh54MalaysianNon-executive Director
Wei Sim Low29MalaysianIndependent Non-Executive Director

Dates and Times for Listing

The proposed listing date for Cilo Cybin is June 25, 2024, at 09h00. This marks a significant milestone for the company as it enters the public market.

Access to Pre-Listing Statement

The Pre-Listing Statement is available in English on the company’s website. Copies can also be obtained at the company’s registered office and the Designated Advisor’s office during business hours.


Cilo Cybin’s listing on the JSE AltX market as a SPAC is a strategic move. It aims to leverage its expertise in biotech and pharmaceuticals. The company’s collaboration with ALPS highlights its commitment to personalized health solutions. Investors are encouraged to review the Pre-Listing Statement for detailed information.